Basen - voglibose
All results are NS for efficacy
diabetes 0.46 [0.34; 0.64]
voglibose 0.2 mg three times daily (n=897)
vs.
placebo (n=881)
double blind
Parallel groups
Sample size: 897/881
Primary endpoint: type 2 diabetes mellitus
FU duration: 4.01 years